LABT

The company's primary development platform is its Bisphosphocin class of compounds, which are designed as a new type of antimicrobial agent. These investigational products are intended to address bacterial infections in various parts of the body, including the skin, bladder, and lungs. A key candidate in its pipeline is Nu-3, a topical antimicrobial gel being studied for the treatment of infected diabetic foot ulcers. This program has advanced into Phase 2b clinical trials.

As a biotechnology firm, Lakewood's business model centers on advancing its drug candidates through clinical development. The company, which was incorporated in 2006 and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in 2025, generates no commercial revenue at this stage. Its operational focus is on research, preclinical studies, and clinical trials, with the goal of demonstrating safety and efficacy to eventually seek regulatory approvals and potential partnerships or commercialization opportunities in the healthcare sector.